Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone609-359-3020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$63.55 million
Profitability
Miscellaneous
Employees165
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
How were Antares Pharma's earnings last quarter?
Antares Pharma Inc (NASDAQ:ATRS) issued its quarterly earnings data on Tuesday, August, 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. The specialty pharmaceutical company earned $28.43 million during the quarter, compared to the consensus estimate of $21.66 million. Antares Pharma had a negative net margin of 4.03% and a negative return on equity of 9.67%. View Antares Pharma's Earnings History.
When is Antares Pharma's next earnings date?
What guidance has Antares Pharma issued on next quarter's earnings?
Antares Pharma issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100-110 million, compared to the consensus revenue estimate of $101.93 million.
What price target have analysts set for ATRS?
4 brokerages have issued 12-month price targets for Antares Pharma's stock. Their predictions range from $1.99 to $8.00. On average, they expect Antares Pharma's share price to reach $5.0350 in the next year. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for Antares Pharma.
What is the consensus analysts' recommendation for Antares Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.
Has Antares Pharma been receiving favorable news coverage?
Press coverage about ATRS stock has trended negative recently, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Antares Pharma earned a news impact score of -2.9 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Antares Pharma.
Are investors shorting Antares Pharma?
Antares Pharma saw a drop in short interest during the month of August. As of August 15th, there was short interest totalling 5,482,300 shares, a drop of 16.8% from the July 15th total of 6,586,500 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 4.9 days. Currently, 3.9% of the shares of the company are short sold. View Antares Pharma's Current Options Chain.
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX), Anika Therapeutics (ANIK), Cerus (CERS) and LeMaitre Vascular (LMAT).
What other stocks do shareholders of Antares Pharma own?
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the folowing people:
- Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
- Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
- Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
- Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
- Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)
Who are Antares Pharma's major shareholders?
Antares Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.69%), Vanguard Group Inc. (4.55%), Sargent Investment Group LLC (1.97%), Cortina Asset Management LLC (1.27%), Northern Trust Corp (1.10%) and Morgan Stanley (0.59%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.
Which major investors are selling Antares Pharma stock?
ATRS stock was sold by a variety of institutional investors in the last quarter, including JW Asset Management LLC, Morgan Stanley, Jefferies Group LLC, Renaissance Technologies LLC, Invesco Ltd., Wells Fargo & Company MN, M&T Bank Corp and Parametric Portfolio Associates LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.
Which major investors are buying Antares Pharma stock?
ATRS stock was acquired by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, BlackRock Inc., River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, Nuveen Asset Management LLC, Asymmetry Capital Management L.P., Fosun International Ltd and Vanguard Group Inc.. View Insider Buying and Selling for Antares Pharma.
How do I buy shares of Antares Pharma?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Antares Pharma's stock price today?
One share of ATRS stock can currently be purchased for approximately $3.55.
How big of a company is Antares Pharma?
Antares Pharma has a market capitalization of $578.87 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.
What is Antares Pharma's official website?
How can I contact Antares Pharma?
Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]
MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
